Sana Biotechnology (SANA) Return on Capital Employed (2021 - 2026)
Sana Biotechnology recorded quarterly Return on Capital Employed of 80.36% in Q1 2026, down 11.54% quarter-over-quarter from 72.05% in Q4 2025, and down 3205.0% year-over-year from 2.59% in Q1 2025.
Sana Biotechnology's Return on Capital Employed history runs 6 years deep, the most recent figure standing at 80.36% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 3205.0% year-over-year to 80.36%; the TTM figure through Mar 2026 stood at 80.36% (down 3205.0% YoY), while the FY2025 annual figure was 65.83%, down 992.0% from the prior year.
- Return on Capital Employed came in at 80.36% for Q1 2026 at Sana Biotechnology, down from 72.05% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 20.89% in Q1 2022 to a low of 80.36% in Q1 2026.
- A 5-year average of 52.08% and a median of 54.91% in 2023 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed soared 2326 bps in 2022 and sank 3205 bps in 2026, its largest moves.
- Sana Biotechnology's Return on Capital Employed stood at 36.39% in 2022, then tumbled by 51 bps to 54.91% in 2023, then fell by 2 bps to 56.26% in 2024, then slipped by 28 bps to 72.05% in 2025, then fell by 12 bps to 80.36% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 80.36%, 72.05%, and 66.11% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Sana Biotechnology | 890.09 Mn | 890.09 Mn | - | -80.36% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -80.36% |
| Dec 31, 2025 | -72.05% |
| Sep 30, 2025 | -66.11% |
| Jun 30, 2025 | -69.77% |
| Mar 31, 2025 | -48.31% |
| Dec 31, 2024 | -56.26% |
| Sep 30, 2024 | -57.65% |
| Jun 30, 2024 | -42.20% |
| Mar 31, 2024 | -56.06% |
| Dec 31, 2023 | -54.91% |
| Sep 30, 2023 | -47.18% |
| Jun 30, 2023 | -59.90% |
| Mar 31, 2023 | -47.64% |
| Dec 31, 2022 | -36.39% |
| Sep 30, 2022 | -36.85% |
| Jun 30, 2022 | -32.81% |
| Mar 31, 2022 | -20.89% |
| Dec 31, 2021 | -32.99% |
| Sep 30, 2021 | -31.10% |
| Jun 30, 2021 | -26.40% |
| Mar 31, 2021 | -44.15% |